ES2351662T3 - Un método para la preparación de dexloxiglumida cristalina. - Google Patents
Un método para la preparación de dexloxiglumida cristalina. Download PDFInfo
- Publication number
- ES2351662T3 ES2351662T3 ES04743871T ES04743871T ES2351662T3 ES 2351662 T3 ES2351662 T3 ES 2351662T3 ES 04743871 T ES04743871 T ES 04743871T ES 04743871 T ES04743871 T ES 04743871T ES 2351662 T3 ES2351662 T3 ES 2351662T3
- Authority
- ES
- Spain
- Prior art keywords
- dexloxiglumide
- preparation
- crystallization
- particles
- isopropyl ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- QNQZBKQEIFTHFZ-GOSISDBHSA-N dexloxiglumide Chemical compound CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 QNQZBKQEIFTHFZ-GOSISDBHSA-N 0.000 title claims abstract description 30
- 229950010525 dexloxiglumide Drugs 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000002425 crystallisation Methods 0.000 claims abstract description 17
- 230000008025 crystallization Effects 0.000 claims abstract description 16
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002245 particle Substances 0.000 claims description 22
- 238000009826 distribution Methods 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 8
- 239000010419 fine particle Substances 0.000 claims description 3
- 238000000691 measurement method Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000000877 morphologic effect Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 description 10
- 239000013078 crystal Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 239000000428 dust Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FJCZHMXAGBYXHJ-QGZVFWFLSA-N (4r)-5-(8-azaspiro[4.5]decan-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-5-oxopentanoic acid Chemical compound N([C@H](CCC(=O)O)C(=O)N1CCC2(CCCC2)CC1)C(=O)C1=CC(Cl)=CC(Cl)=C1 FJCZHMXAGBYXHJ-QGZVFWFLSA-N 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- 102100021942 C-C motif chemokine 28 Human genes 0.000 description 1
- 229940122623 CCK receptor antagonist Drugs 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 102000004859 Cholecystokinin Receptors Human genes 0.000 description 1
- 108090001085 Cholecystokinin Receptors Proteins 0.000 description 1
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 1
- QNQZBKQEIFTHFZ-UHFFFAOYSA-N Loxizin Chemical compound CCCCCN(CCCOC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 QNQZBKQEIFTHFZ-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 208000003770 biliary dyskinesia Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 229950009386 loxiglumide Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 229950011476 spiroglumide Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITTO03A0474 | 2003-06-23 | ||
| IT000474A ITTO20030474A1 (it) | 2003-06-23 | 2003-06-23 | Procedimento per la preparazione di dexloxiglumide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2351662T3 true ES2351662T3 (es) | 2011-02-09 |
Family
ID=33524063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04743871T Expired - Lifetime ES2351662T3 (es) | 2003-06-23 | 2004-06-21 | Un método para la preparación de dexloxiglumida cristalina. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7662994B2 (https=) |
| EP (1) | EP1646607B1 (https=) |
| JP (1) | JP5197955B2 (https=) |
| AT (1) | ATE478839T1 (https=) |
| AU (1) | AU2004249526B2 (https=) |
| CA (1) | CA2529018C (https=) |
| DE (1) | DE602004028830D1 (https=) |
| DK (1) | DK1646607T3 (https=) |
| ES (1) | ES2351662T3 (https=) |
| IT (1) | ITTO20030474A1 (https=) |
| PT (1) | PT1646607E (https=) |
| WO (1) | WO2004113271A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863330B2 (en) * | 2006-06-14 | 2011-01-04 | Rottapharm S.P.A. | Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1217123B (it) * | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
| ES2078447T3 (es) * | 1990-06-15 | 1995-12-16 | Merck & Co Inc | Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales. |
| US7122083B2 (en) * | 2002-04-02 | 2006-10-17 | E. I. Du Pont De Nemours And Company | Apparatus and process used in growing crystals |
-
2003
- 2003-06-23 IT IT000474A patent/ITTO20030474A1/it unknown
-
2004
- 2004-06-21 JP JP2006516595A patent/JP5197955B2/ja not_active Expired - Fee Related
- 2004-06-21 CA CA2529018A patent/CA2529018C/en not_active Expired - Fee Related
- 2004-06-21 DK DK04743871.8T patent/DK1646607T3/da active
- 2004-06-21 AU AU2004249526A patent/AU2004249526B2/en not_active Ceased
- 2004-06-21 WO PCT/IB2004/002208 patent/WO2004113271A2/en not_active Ceased
- 2004-06-21 PT PT04743871T patent/PT1646607E/pt unknown
- 2004-06-21 US US10/562,013 patent/US7662994B2/en not_active Expired - Fee Related
- 2004-06-21 ES ES04743871T patent/ES2351662T3/es not_active Expired - Lifetime
- 2004-06-21 DE DE602004028830T patent/DE602004028830D1/de not_active Expired - Lifetime
- 2004-06-21 EP EP04743871A patent/EP1646607B1/en not_active Expired - Lifetime
- 2004-06-21 AT AT04743871T patent/ATE478839T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| DK1646607T3 (da) | 2010-11-22 |
| WO2004113271A8 (en) | 2005-05-06 |
| ITTO20030474A1 (it) | 2004-12-24 |
| WO2004113271A2 (en) | 2004-12-29 |
| HK1089750A1 (en) | 2006-12-08 |
| PT1646607E (pt) | 2010-10-12 |
| WO2004113271A3 (en) | 2005-01-27 |
| EP1646607A2 (en) | 2006-04-19 |
| AU2004249526A1 (en) | 2004-12-29 |
| CA2529018A1 (en) | 2004-12-29 |
| US7662994B2 (en) | 2010-02-16 |
| CA2529018C (en) | 2013-05-28 |
| AU2004249526B2 (en) | 2011-02-24 |
| EP1646607B1 (en) | 2010-08-25 |
| JP2007521253A (ja) | 2007-08-02 |
| ATE478839T1 (de) | 2010-09-15 |
| JP5197955B2 (ja) | 2013-05-15 |
| US20060154987A1 (en) | 2006-07-13 |
| DE602004028830D1 (de) | 2010-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12384743B2 (en) | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof | |
| US8609665B2 (en) | Solvate and crystalline forms of carbamoyl-cyclohexane derivatives | |
| CN103842360B (zh) | 用于药物制剂的具有特定粒度分布范围和比表面积范围的n-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物 | |
| ES2529562T3 (es) | Un derivado de 1-(1H-1,2,4-triazol-1-il)butan-2-ol para uso farmacéutico, y el uso de un derivado de 1-(1H-1,2,4-triazol-1-il)butan-2-ol con forma cristalina sustancialmente indefinida para preparar dicho derivado de 1-(1H-1,2,4-triazol-1-il)butan-2-ol | |
| US20250312301A1 (en) | Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof | |
| JP6230743B1 (ja) | ヘテロシクリデンアセトアミド誘導体の結晶 | |
| US9527803B2 (en) | Crystal form VII of agomelatine, preparation method and use thereof and pharmaceutical composition containing same | |
| ES2412357T3 (es) | Cocristales de metronidazol | |
| BR112019012340A2 (pt) | sais cristalinos e polimorfos de um antagonista p2x3 | |
| US10961192B2 (en) | (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method therefor, and application thereof | |
| ES2351662T3 (es) | Un método para la preparación de dexloxiglumida cristalina. | |
| US11643415B1 (en) | Rabeximod compounds | |
| US8729130B2 (en) | Methods of using novel solid forms of tacedinaline | |
| WO2004076403A1 (en) | Sumatriptan crystalline forms, pharmaceutical compositions and methods | |
| US20230105181A1 (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine | |
| Williams | Physical form | |
| Weyna | Crystal Engineering of Multiple Component Crystal Forms of Active Pharmaceutical Ingredients | |
| ES2349798T3 (es) | Hidrato variable cristalino de la sal hemisuccinato de (s)-6-(4-(2-((3-(9h-carbazol-4-iloxi)-2-hidroxipropil)amino)-2-metilpropil)fenoxi)-3-piridinocarboxamida. | |
| Patil et al. | Journal of Pharmaceutical Technology Research and Management |